Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2001;98:434-439
© 2001 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Creinin, M. D.
Right arrow Articles by Schwartz, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Creinin, M. D.
Right arrow Articles by Schwartz, J. L.

ORIGINAL RESEARCH

Mifepristone 100 mg in Abortion Regimens

Mitchell D. Creinin, MD, Helen C. Pymar, MD and Jill L. Schwartz, MD

From the Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Women’s Research Institute Family Planning Research Fund, Pittsburgh, Pennsylvania.

Address reprint requests to: Mitchell D. Creinin, MD, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Magee-Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213-3180; E-mail: mcreinin{at}mail.magee.edu.

OBJECTIVE: To examine the clinical efficacy of mifepristone 100 mg followed 2 days later by misoprostol 400 µg orally or 800 µg vaginally in women at up to 49 days’ gestation.

METHODS: Eighty participants received mifepristone 100 mg and then were randomized to misoprostol, administered 48 hours later, at a dose of 400 µg orally (group 1) or 800 µg vaginally (group 2). Women returned for follow-up evaluations 24 ± 1 hour after using the misoprostol and then 2–3 weeks later. If abortion still had not occurred and the pregnancy was nonviable, the subject returned again after an additional 3 weeks.

RESULTS: Twenty-four hours after receiving misoprostol, 34 (85%; 95% confidence interval [CI] 71%, 94%) of the 40 women in group 1 and 38 (95%; 95% CI 85%, 99%) of the 40 women in group 2 had complete abortions. Overall, complete abortion without surgical intervention occurred in 34 women in group 1 (85%; 95% CI 71%, 94%) and 40 women in group 2 (100%; 95% CI 91%, 100%; P = .03). Four women in group 1 required suction aspiration for continuing pregnancy at the second follow-up, compared with none in group 2 (P = .12). Side effects occurred with similar frequency in both treatment groups.

CONCLUSION: Low-dose mifepristone (100 mg) combined with vaginal misoprostol 800 µg may be an effective alternative to regimens using 200 or 600 mg of mifepristone with misoprostol.




This article has been cited by other articles:


Home page
 Hum ReprodHome page
A. Ben-Chetrit, T. Eldar-Geva, T. Lindenberg, M. Farhat, S. Shimonovitz, D. Zacut, H. Gelber, R. Sitruk-Ware, and I. M. Spitz
Mifepristone does not induce cervical softening in non-pregnant women
Hum. Reprod., October 1, 2004; 19(10): 2372 - 2376.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Nurs.Home page
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs., January 1, 2003; 6(1): e1 - 1.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
J. K. Jain, C. Dutton, B. Harwood, K. R. Meckstroth, and D. R. Mishell Jr
A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy
Hum. Reprod., June 1, 2002; 17(6): 1477 - 1482.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Obstetricians and Gynecologists.